Bruker Co. (NASDAQ:BRKR) Receives Consensus Rating of “Buy” from Analysts

Bruker Co. (NASDAQ:BRKR) has been given a consensus rating of “Buy” by the fourteen research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $49.33.

BRKR has been the subject of a number of research reports. Jefferies Financial Group raised their target price on Bruker from $45.00 to $56.00 and gave the company a “buy” rating in a research note on Friday, June 21st. BidaskClub upgraded Bruker from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 22nd. Svb Leerink upgraded Bruker from a “market perform” rating to an “outperform” rating and raised their target price for the company from $40.00 to $53.00 in a research note on Friday, May 3rd. Leerink Swann upgraded Bruker from a “market perform” rating to an “outperform” rating in a research note on Friday, May 3rd. Finally, Needham & Company LLC restated a “strong-buy” rating and issued a $46.00 target price (up from $39.00) on shares of Bruker in a research note on Monday, May 6th.

In related news, Director Marc A. Kastner sold 1,374 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $41.79, for a total value of $57,419.46. Following the transaction, the director now owns 10,811 shares in the company, valued at $451,791.69. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Frank H. Laukien sold 400,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $41.48, for a total value of $16,592,000.00. Following the completion of the transaction, the chief executive officer now owns 37,991,030 shares in the company, valued at approximately $1,575,867,924.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 801,374 shares of company stock worth $33,241,419. 26.50% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in Bruker by 2.6% in the fourth quarter. BlackRock Inc. now owns 5,465,722 shares of the medical research company’s stock valued at $162,713,000 after acquiring an additional 139,004 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Bruker by 5.5% during the first quarter. Acadian Asset Management LLC now owns 4,212,522 shares of the medical research company’s stock worth $161,930,000 after buying an additional 220,700 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Bruker by 10.7% during the first quarter. Janus Henderson Group PLC now owns 3,298,436 shares of the medical research company’s stock worth $126,792,000 after buying an additional 319,125 shares during the last quarter. AJO LP boosted its holdings in Bruker by 9.0% during the first quarter. AJO LP now owns 2,229,209 shares of the medical research company’s stock worth $85,691,000 after buying an additional 183,548 shares during the last quarter. Finally, Norges Bank bought a new position in Bruker during the fourth quarter worth about $49,346,000. Institutional investors and hedge funds own 66.73% of the company’s stock.

Bruker stock traded up $1.00 during mid-day trading on Friday, hitting $49.95. 1,979,414 shares of the company were exchanged, compared to its average volume of 811,645. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.12 and a quick ratio of 1.27. The business has a fifty day moving average of $44.19. Bruker has a 1-year low of $26.10 and a 1-year high of $51.13. The company has a market capitalization of $7.68 billion, a P/E ratio of 35.68, a PEG ratio of 2.40 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, May 2nd. The medical research company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.04. Bruker had a return on equity of 26.28% and a net margin of 9.53%. The firm had revenue of $461.40 million during the quarter, compared to analyst estimates of $450.46 million. During the same period in the prior year, the company posted $0.24 earnings per share. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. Research analysts anticipate that Bruker will post 1.62 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, June 21st. Investors of record on Monday, June 3rd were issued a $0.04 dividend. This represents a $0.16 annualized dividend and a yield of 0.32%. The ex-dividend date of this dividend was Friday, May 31st. Bruker’s dividend payout ratio is 11.43%.

Bruker Company Profile

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Read More: What is the 52-week high/low?

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.